当前位置: 首页 >> 检索结果
441. Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
作者: Connie N Hess.;E Sebastian Debus.;Mark R Nehler.;Sonia S Anand.;Manesh R Patel.;Michael Szarek.;Warren H Capell.;Judith Hsia.;Joshua A Beckman.;Marianne Brodmann.;Rafael Diaz.;Peter Habertheuer.;Nicholas J Leeper.;Richard J Powell.;Henrik Sillesen.;Eva Muehlhofer.;Scott D Berkowitz.;Lloyd P Haskell.;Rupert M Bauersachs.;Marc P Bonaca.
来源: Circulation. 2021年144卷23期1831-1841页
Patients with peripheral artery disease (PAD) are at heightened risk of acute limb ischemia (ALI), a thrombotic event associated with amputation, disability, and mortality. Previous lower extremity revascularization (LER) is associated with increased ALI risk in chronic PAD. However, the pattern of risk, clinical correlates, and outcomes after ALI early after LER are not well-studied, and effective therapies to reduce ALI post-LER are lacking.
442. A Novel Visually Guided Radiofrequency Balloon Ablation Catheter for Pulmonary Vein Isolation: One-Year Outcomes of the Multicenter AF-FICIENT I Trial.
作者: Vivek Y Reddy.;Amin Al-Ahmad.;Audrius Aidietis.;Matthew Daly.;Iain Melton.;Yan Hu.;Matthew Sulkin.;Gediminas Rackauskas.;Adrian Ebner.;Darren A Hooks.;Aamir Sofi.;Petr Neužil.;Ian G Crozier.
来源: Circ Arrhythm Electrophysiol. 2021年14卷10期e009308页
[Figure: see text].
443. Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial.
作者: James A Blumenthal.;Alan L Hinderliter.;Patrick J Smith.;Stephanie Mabe.;Lana L Watkins.;Linda Craighead.;Krista Ingle.;Crystal Tyson.;Pao-Hwa Lin.;William E Kraus.;Lawrence Liao.;Andrew Sherwood.
来源: Circulation. 2021年144卷15期1212-1226页
Although lifestyle modifications generally are effective in lowering blood pressure (BP) among patients with unmedicated hypertension and in those treated with 1 or 2 antihypertensive agents, the value of exercise and diet for lowering BP in patients with resistant hypertension is unknown.
444. One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction.
作者: Michinari Hieda.;Satyam Sarma.;Christopher M Hearon.;James P MacNamara.;Katrin A Dias.;Mitchel Samels.;Dean Palmer.;Sheryl Livingston.;Margot Morris.;Benjamin D Levine.
来源: Circulation. 2021年144卷12期934-946页
Individuals with left ventricular (LV) hypertrophy and elevated cardiac biomarkers in middle age are at increased risk for the development of heart failure with preserved ejection fraction. Prolonged exercise training reverses the LV stiffening associated with healthy but sedentary aging; however, whether it can also normalize LV myocardial stiffness in patients at high risk for heart failure with preserved ejection fraction is unknown. In a prospective, randomized controlled trial, we hypothesized that 1-year prolonged exercise training would reduce LV myocardial stiffness in patients with LV hypertrophy.
445. No-Touch Versus Conventional Vein Harvesting Techniques at 12 Months After Coronary Artery Bypass Grafting Surgery: Multicenter Randomized, Controlled Trial.
作者: Meice Tian.;Xianqiang Wang.;Hansong Sun.;Wei Feng.;Yunhu Song.;Feng Lu.;Liqing Wang.;Yang Wang.;Bo Xu.;Huaibin Wang.;Su Liu.;Zhigang Liu.;Yu Chen.;Qi Miao.;Pixiong Su.;Yan Yang.;Shaoxian Guo.;Bin Lu.;Zhiqiang Sun.;Kaiyang Liu.;Changwei Zhang.;Yue Wu.;Haitao Xu.;Wei Zhao.;Chao Han.;Xingtong Zhou.;Enshi Wang.;Xiaoning Huo.;Shengshou Hu.
来源: Circulation. 2021年144卷14期1120-1129页
Vein graft occlusion is deemed a major challenge in coronary artery bypass grafting. Previous studies implied that the no-touch technique for vein graft harvesting could reduce occlusion rate compared with the conventional approach; however, evidence on the clinical benefit and generalizability of the no-touch technique is scare.
446. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
作者: Kai-Ni Shen.;Wei-Jun Fu.;Yu Wu.;Yu-Jun Dong.;Zhong-Xia Huang.;Yong-Qiang Wei.;Chun-Rui Li.;Chun-Yan Sun.;Ye Chen.;Hui-Lei Miao.;Yue-Lun Zhang.;Xin-Xin Cao.;Dao-Bin Zhou.;Jian Li.
来源: Circulation. 2022年145卷1期8-17页
Doxycycline was demonstrated in a retrospective study to be associated with greater survival in patients with light chain amyloidosis. Therefore, we prospectively compared the efficacy of bortezomib-cyclophosphamide-dexamethasone (CyBorD) and CyBorD combined with doxycycline for cardiac light chain amyloidosis.
447. Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity.
作者: Harmony R Reynolds.;Leslee J Shaw.;James K Min.;Courtney B Page.;Daniel S Berman.;Bernard R Chaitman.;Michael H Picard.;Raymond Y Kwong.;Sean M O'Brien.;Zhen Huang.;Daniel B Mark.;Ranjit K Nath.;Sudhanshu K Dwivedi.;Paola E P Smanio.;Peter H Stone.;Claes Held.;Matyas Keltai.;Sripal Bangalore.;Jonathan D Newman.;John A Spertus.;Gregg W Stone.;David J Maron.;Judith S Hochman.
来源: Circulation. 2021年144卷13期1024-1038页
The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) postulated that patients with stable coronary artery disease (CAD) and moderate or severe ischemia would benefit from revascularization. We investigated the relationship between severity of CAD and ischemia and trial outcomes, overall and by management strategy.
448. Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study.
作者: Matthias Thielmann.;David Corteville.;Gabor Szabo.;Madhav Swaminathan.;Andre Lamy.;Lukas J Lehner.;Craig D Brown.;Nicolas Noiseux.;Mohamed G Atta.;Elizabeth C Squiers.;Shai Erlich.;Daniel Rothenstein.;Bruce Molitoris.;C David Mazer.
来源: Circulation. 2021年144卷14期1133-1144页
Acute kidney injury (AKI) affects up to 30% of patients undergoing cardiac surgery, leading to increased in-hospital and long-term morbidity and mortality. Teprasiran is a novel small interfering RNA that temporarily inhibits p53-mediated cell death that underlies AKI.
449. Cryoballoon Versus High-Power, Short-Duration Radiofrequency Ablation for Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation: A Single-Center, Prospective, Randomized Study.
作者: Hui-Nam Pak.;Je-Wook Park.;Song-Yi Yang.;Tae-Hoon Kim.;Jae-Sun Uhm.;Boyoung Joung.;Moon-Hyoung Lee.;Hee Tae Yu.
来源: Circ Arrhythm Electrophysiol. 2021年14卷9期e010040页
[Figure: see text].
450. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.
作者: Dhanunjaya Lakkireddy.;David Thaler.;Christopher R Ellis.;Vijendra Swarup.;Lars Sondergaard.;John Carroll.;Michael R Gold.;James Hermiller.;Hans-Christoph Diener.;Boris Schmidt.;Lee MacDonald.;Moussa Mansour.;Brijeshwar Maini.;Laura O'Brien.;Stephan Windecker.
来源: Circulation. 2021年144卷19期1543-1552页
Percutaneous closure of the left atrial appendage (LAA) is an alternative to chronic oral anticoagulation to reduce stroke risk in patients with nonvalvular atrial fibrillation. The Amulet IDE trial (Amplatzer Amulet Left Atrial Appendage Occluder IDE Trial) was designed to evaluate the safety and effectiveness of the dual-seal mechanism of the Amulet LAA occluder compared with the Watchman device.
451. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
作者: Renato D Lopes.;Celestia S Higano.;Susan F Slovin.;Adam J Nelson.;Robert Bigelow.;Per S Sørensen.;Chiara Melloni.;Shaun G Goodman.;Christopher P Evans.;Jan Nilsson.;Deepak L Bhatt.;Noel W Clarke.;Tine K Olesen.;Belinda T Doyle-Olsen.;Henriette Kristensen.;Lauren Arney.;Matthew T Roe.;John H Alexander.; .
来源: Circulation. 2021年144卷16期1295-1307页
The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial.
452. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
作者: Milton Packer.;Javed Butler.;Faiez Zannad.;Gerasimos Filippatos.;Joao Pedro Ferreira.;Stuart J Pocock.;Peter Carson.;Inder Anand.;Wolfram Doehner.;Markus Haass.;Michel Komajda.;Alan Miller.;Steen Pehrson.;John R Teerlink.;Sven Schnaidt.;Cordula Zeller.;Janet M Schnee.;Stefan D Anker.
来源: Circulation. 2021年144卷16期1284-1294页
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart failure events.
453. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.
作者: Ole Fröbert.;Matthias Götberg.;David Erlinge.;Zubair Akhtar.;Evald H Christiansen.;Chandini R MacIntyre.;Keith G Oldroyd.;Zuzana Motovska.;Andrejs Erglis.;Rasmus Moer.;Ota Hlinomaz.;Lars Jakobsen.;Thomas Engstrøm.;Lisette O Jensen.;Christian O Fallesen.;Svend E Jensen.;Oskar Angerås.;Fredrik Calais.;Amra Kåregren.;Jörg Lauermann.;Arash Mokhtari.;Johan Nilsson.;Jonas Persson.;Per Stalby.;Abu K M M Islam.;Afzalur Rahman.;Fazila Malik.;Sohel Choudhury.;Timothy Collier.;Stuart J Pocock.;John Pernow.
来源: Circulation. 2021年144卷18期1476-1484页
Observational and small, randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease.
454. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial.
作者: Pieter C Smits.;Enrico Frigoli.;Jan Tijssen.;Peter Jüni.;Pascal Vranckx.;Yukio Ozaki.;Marie-Claude Morice.;Bernard Chevalier.;Yoshinobu Onuma.;Stephan Windecker.;Pim A L Tonino.;Marco Roffi.;Maciej Lesiak.;Felix Mahfoud.;Jozef Bartunek.;David Hildick-Smith.;Antonio Colombo.;Goran Stankovic.;Andrés Iñiguez.;Carl Schultz.;Ran Kornowski.;Paul J L Ong.;Mirvat Alasnag.;Alfredo E Rodriguez.;Aris Moschovitis.;Peep Laanmets.;Dik Heg.;Marco Valgimigli.; .
来源: Circulation. 2021年144卷15期1196-1211页
The optimal duration of antiplatelet therapy (APT) in patients at high bleeding risk with or without oral anticoagulation (OAC) after coronary stenting remains unclear.
455. Effects of Walnut Consumption for 2 Years on Lipoprotein Subclasses Among Healthy Elders: Findings From the WAHA Randomized Controlled Trial.
作者: Sujatha Rajaram.;Montserrat Cofán.;Aleix Sala-Vila.;Ella Haddad.;Mercè Serra-Mir.;Edward Bitok.;Irene Roth.;Tania M Freitas-Simoes.;Amandeep Kaur.;Cinta Valls-Pedret.;Mónica Doménech.;Keiji Oda.;Dolores Corella.;Joan Sabaté.;Emilio Ros.
来源: Circulation. 2021年144卷13期1083-1085页 456. Compared Outcomes of ST-Segment-Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial.
作者: Pierre Denormandie.;Tabassome Simon.;Guillaume Cayla.;Philippe Gabriel Steg.;Gilles Montalescot.;Isabelle Durand-Zaleski.;Alicia le Bras.;Hervé le Breton.;Yann Valy.;François Schiele.;Thomas Cuisset.;Gérald Vanzetto.;Sébastien Levesque.;Pascal Goube.;Olivier Nallet.;Denis Angoulvant.;François Roubille.;Anaïs Charles Nelson.;Gilles Chatellier.;Nicolas Danchin.;Etienne Puymirat.
来源: Circ Cardiovasc Interv. 2021年14卷11期e011314页
In patients with ST-segment-elevation myocardial infarction and multivessel disease, percutaneous coronary intervention (PCI) for nonculprit lesions guided by fractional flow reserve (FFR) is superior to treatment of the culprit lesion alone. Whether deferring nonculprit PCI is safe in this specific context is questionable. We aimed to assess clinical outcomes at 1 year in ST-segment-elevation myocardial infarction patients with multivessel coronary artery disease and an FFR-guided strategy for nonculprit lesions, according to whether or not ≥1 PCI was performed.
457. Catheter-Based Adrenal Ablation Remits Primary Aldosteronism: A Randomized Medication-Controlled Trial.
作者: Zhigang Zhao.;Xiaoli Liu.;Hexuan Zhang.;Qiang Li.;Hongbo He.;Zhencheng Yan.;Fang Sun.;Yingsha Li.;Xunmei Zhou.;Xiaona Bu.;Hao Wu.;Rufei Shen.;Hongting Zheng.;Gangyi Yang.;Zhiming Zhu.; .
来源: Circulation. 2021年144卷7期580-582页 458. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
作者: E Sebastian Debus.;Mark R Nehler.;Nicholas Govsyeyev.;Rupert M Bauersachs.;Sonia S Anand.;Manesh R Patel.;Fabrizio Fanelli.;Warren H Capell.;Taylor Brackin.;Franz Hinterreiter.;Dainis Krievins.;Patrice Nault.;Gabriele Piffaretti.;Alexei Svetlikov.;Nicole Jaeger.;Connie N Hess.;Henrik H Sillesen.;Michael Conte.;Joseph Mills.;Eva Muehlhofer.;Lloyd P Haskell.;Scott D Berkowitz.;William R Hiatt.;Marc P Bonaca.
来源: Circulation. 2021年144卷14期1104-1116页
Patients with peripheral artery disease requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic Acid] Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) demonstrated that rivaroxaban significantly reduced this risk. The efficacy and safety of rivaroxaban has not been described in patients who underwent surgical LER.
459. Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study.
作者: Dean J Kereiakes.;Robert L Feldman.;A J J Ijsselmuiden.;Shigeru Saito.;Giovanni Amoroso.;James P Zidar.;S Chiu Wong.;Pieter Stella.;Steven Yakubov.;John Lasala.;David J Cohen.;Gheorghe Doros.;Donald E Cutlip.;Sunil V Rao.
来源: Circ Cardiovasc Interv. 2021年14卷9期e010609页
[Figure: see text].
460. Placebo-Controlled Efficacy of Percutaneous Coronary Intervention for Focal and Diffuse Patterns of Stable Coronary Artery Disease.
作者: Christopher A Rajkumar.;Matthew Shun-Shin.;Henry Seligman.;Yousif Ahmad.;Takayuki Warisawa.;Christopher M Cook.;James P Howard.;Sashiananthan Ganesananthan.;Laura Amarin.;Caitlin Khan.;Ayesha Ahmed.;Alexandra Nowbar.;Michael Foley.;Ravi Assomull.;Niall G Keenan.;Joban Sehmi.;Thomas R Keeble.;John R Davies.;Kare H Tang.;Robert Gerber.;Graham Cole.;Peter O'Kane.;Andrew S P Sharp.;Ramzi Khamis.;Gajen Kanaganayagam.;Ricardo Petraco.;Neil Ruparelia.;Iqbal S Malik.;Sukhjinder Nijjer.;Sayan Sen.;Darrel P Francis.;Rasha Al-Lamee.
来源: Circ Cardiovasc Interv. 2021年14卷8期e009891页
[Figure: see text].
|